Autoimmune Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Autoimmune clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 74 trials

Recruiting
Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Early Phase 1

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

Sjogren's SyndromeAutoimmune DiseasesIdiopathic Inflammatory Myopathies+3 more
Nanjing Bioheng Biotech Co., Ltd.20 enrolled1 locationNCT06548607
Recruiting
Phase 2

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

PreventionDiabetes Mellitus, Type 1Autoimmune Diseases
Diamyd Medical AB16 enrolled1 locationNCT05683990
Recruiting

Ovarian Tissue Cryopreservation for Fertility Preservation

CancerAutoimmune Diseases
University of Pittsburgh500 enrolled1 locationNCT05875155
Recruiting

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

Inflammatory Bowel DiseasesHeart DiseasesAutoimmune Disease+5 more
University of Chicago1,200 enrolled1 locationNCT01280825
Recruiting
Phase 1

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company125 enrolled28 locationsNCT07115745
Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

Metabolic DiseaseDiabetes Mellitus, Type 1Type 1 Diabetes+14 more
Otsuka Pharmaceutical Factory, Inc.13 enrolled1 locationNCT06575426
Recruiting
Phase 1

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.32 enrolled8 locationsNCT06680037
Recruiting
Early Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
Changhai Hospital60 enrolled1 locationNCT07246096
Recruiting

Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults

Type 1 Diabetes MellitusLatent Autoimmune Diabetes in Adult (LADA)
Fondazione IRCCS Policlinico San Matteo di Pavia75 enrolled1 locationNCT07434154
Recruiting

Biologics And Clinical Immunology Cohort at Sinai

Autoimmune DiseasesImmunological DiseasePrimary Immune Deficiency
Icahn School of Medicine at Mount Sinai800 enrolled1 locationNCT04784364
Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting

National Longitudinal Cohort of Hematological Diseases

Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Phase 1Phase 2

Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease

Malignant TumorHyperthyroidism, AutoimmuneCardiovascular Abnormalities
Peking Union Medical College Hospital600 enrolled1 locationNCT07400224
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting

Montreal Immune-Related Adverse Events (MIRAE) Study

CancerAutoimmune DiseasesImmune System Disorder+1 more
Sir Mortimer B. Davis - Jewish General Hospital1,000 enrolled1 locationNCT05139706
Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Traumatic Brain InjuryEhlers-Danlos SyndromePost-Acute COVID-19 Syndrome+41 more
Brain Inflammation Collaborative10,000 enrolled1 locationNCT04806620
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Daishi Tian36 enrolled1 locationNCT07337785
Recruiting
Not Applicable

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

Diabetes MellitusDiabetes Mellitus, Type 2Diabetes+8 more
University of Colorado, Denver240 enrolled2 locationsNCT07011147
Recruiting
Phase 1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094